These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38788675)

  • 21. Blood biomarkers of traumatic brain injury and cognitive impairment in older veterans.
    Peltz CB; Kenney K; Gill J; Diaz-Arrastia R; Gardner RC; Yaffe K
    Neurology; 2020 Sep; 95(9):e1126-e1133. PubMed ID: 32571850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Examination of the Longitudinal Relationship Between Cognitive Function and Physical Activity Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.
    Tometich DB; Mosher CE; Cyders M; McDonald BC; Saykin AJ; Small BJ; Zhai W; Zhou X; Jim HSL; Jacobsen P; Ahles TA; Root JC; Graham D; Patel SK; Mandelblatt J
    Ann Behav Med; 2023 Apr; 57(3):237-248. PubMed ID: 36356044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population.
    Ohara T; Tatebe H; Hata J; Honda T; Shibata M; Matsuura S; Mikami T; Maeda T; Ono K; Mimura M; Nakashima K; Iga JI; Takebayashi M; Tokuda T; Ninomiya T;
    Psychiatry Clin Neurosci; 2024 Jun; 78(6):362-371. PubMed ID: 38606661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of exercise on blood-based biomarkers of Alzheimer's disease in cognitively unimpaired older adults.
    Sewell KR; Rainey-Smith SR; Pedrini S; Peiffer JJ; Sohrabi HR; Taddei K; Markovic SJ; Martins RN; Brown BM
    Geroscience; 2024 Dec; 46(6):5911-5923. PubMed ID: 38488949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
    Ramanan VK; Graff-Radford J; Syrjanen J; Shir D; Algeciras-Schimnich A; Lucas J; Martens YA; Carrasquillo MM; Day GS; Ertekin-Taner N; Lachner C; Willis FB; Knopman DS; Jack CR; Petersen RC; Vemuri P; Graff-Radford N; Mielke MM
    Neurology; 2023 Oct; 101(14):e1402-e1411. PubMed ID: 37580163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer's disease signature regions and predicted future tau deposition.
    Hu Q; Shi M; Li Y; Zhao X
    BMC Neurol; 2024 Jul; 24(1):236. PubMed ID: 38971733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE.
    Yu X; Shi R; Zhou X; Zhang M; Cai Y; Jiang J; Han Y
    Alzheimers Dement; 2024 Sep; 20(9):6170-6182. PubMed ID: 38982860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychosis in Alzheimer Disease and Elevations in Disease-Relevant Biomarkers.
    Gomar JJ; Koppel J
    JAMA Psychiatry; 2024 Aug; 81(8):834-839. PubMed ID: 38922609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central autonomic network dysfunction and plasma Alzheimer's disease biomarkers in older adults.
    Lohman T; Kapoor A; Engstrom AC; Shenasa F; Alitin JPM; Gaubert A; Rodgers KE; Bradford D; Mather M; Han SD; Head E; Sordo L; Thayer JF; Nation DA
    Alzheimers Res Ther; 2024 Jun; 16(1):124. PubMed ID: 38851772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
    Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
    Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's Disease and Cognitive Decline in Patients with Cardiovascular Diseases Along the Heart-Brain Axis.
    Trieu C; van Harten AC; Leeuwis AE; Exalto LG; Hooghiemstra AM; Verberk IMW; Allaart CP; Brunner-La Rocca HP; Kappelle LJ; van Oostenbrugge RJ; Biessels GJ; Teunissen CE; van der Flier WM;
    J Alzheimers Dis; 2024; 98(3):987-1000. PubMed ID: 38489178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
    Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
    ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
    Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
    JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
    Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
    Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
    Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
    JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.